Sugi Predict

Sugi Predict / Compounds / SCHEMBL21884434

SCHEMBL21884434

SCHEMBL21884434

N#Cc1ccc(O)c(C(=O)NC(=N)N)c1-c1ccccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ HPGD P15428 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ GAA P10253 3/20 0.36
▸ PPIA P62937 3/20 0.33
▸ S1PR3 Q99500 2/20 0.33
▸ EPAS1 Q99814 1/20 0.33
▸ AR P10275 1/20 0.33
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21884572 0.91 TAS1R3 (0.33) L3MBTL1KDM4EALDH1A1HPGDTSHR
SCHEMBL21884631 0.89 ESR2 (0.36) MEN1KMT2ASMN1; SMN2GAAPPIA
SCHEMBL21884394 0.89 MAPT (0.34) L3MBTL1KDM4EALDH1A1HPGDTSHR
SCHEMBL21884438 0.89 PPIA (0.33) L3MBTL1KDM4EALDH1A1HPGDTSHR
SCHEMBL21884360 0.87 MEN1 (0.33) L3MBTL1KDM4EALDH1A1HPGDTSHR
SCHEMBL21884530 0.86 TMPRSS4 (0.40) ALDH1A1PPIAS1PR3LMNA
SCHEMBL21884383 0.86 L3MBTL1 (0.38) L3MBTL1KDM4EALDH1A1HPGDTSHR
SCHEMBL21884627 0.86 PPIA (0.33) KDM4EALDH1A1HPGDTSHRHTT
SCHEMBL21884788 0.86 PPIA (0.40) L3MBTL1ALDH1A1MEN1KMT2APPIA
SCHEMBL21884443 0.84 PPIA (0.38) ALDH1A1MEN1KMT2APPIAS1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 — — US disclosed
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 — — US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
WO-2020061473-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY SLC19A1, SLC1A5, SLC1A2 L3MBTL1 1302/4885KDM4E 2932/4885ALDH1A1 1823/4885
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS SNRPE, G3BP1, G3BP2 L3MBTL1 54/4885KDM4E 4324/4885ALDH1A1 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.